Health Canada grants approval for Ocaliva(TM) (obeticholic acid) for reatment of PBC
Intercept Pharmaceuticals announced that Health Canada has granted a conditional approval for Ocaliva (obeticholic acid) for treatment of primary biliary cholangitis, when used in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA. May 25, 2017